According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

### Moxifloxacin Solid Formulation

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.5     | 28.09.2024     | 9839712-00009 | Date of first issue: 13.10.2021 |

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

| 1.1 | Product identifier<br>Trade name                 | :    | Moxifloxacin Solid Formulation                         |
|-----|--|------|--|
| 1.2 | Relevant identified uses of th                   | ne s | ubstance or mixture and uses advised against           |
|     | Use of the Sub-<br>stance/Mixture                |      | Pharmaceutical   |
|     | Recommended restrictions on use                  | :    | Not applicable   |
| 1.3 | Details of the supplier of the                   | saf  | ety data sheet   |
|     | Company  | :    | MSD<br>120 Moorgate<br>EC2M 6UR London, United Kingdom |
|     | Telephone  | :    | +44 (0) 2081548000                                     |
|     | E-mail address of person responsible for the SDS | :    | EHSDATASTEWARD@msd.com                                 |

### **1.4 Emergency telephone number**

1-908-423-6000

### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

# Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Acute toxicity, Category 4 Eye irritation, Category 2 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure, Category 2 H302: Harmful if swallowed.H319: Causes serious eye irritation.H361d: Suspected of damaging the unborn child.H373: May cause damage to organs through prolonged or repeated exposure.

#### 2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



### **Moxifloxacin Solid Formulation**

| Version<br>3.5    | Revision Date: 28.09.2024 | SDS Numbe<br>9839712-00                            |   |
|-------------------|---------------------------|--|---|
| Hazard pictograms |                           |  |   |
| Signa             | l word                    | : Warning  | •   |
| Haza              | rd statements             | : H302<br>H319<br>H361d<br>H373                    | Harmful if swallowed.<br>Causes serious eye irritation.<br>Suspected of damaging the unborn child.<br>May cause damage to organs through prolonged<br>or repeated exposure.                     |
| Preca             | utionary statements       | : <b>Preventio</b><br>P201<br>P270<br>P280         | Don:<br>Obtain special instructions before use.<br>Do not eat, drink or smoke when using this prod-<br>uct.<br>Wear protective gloves/ protective clothing/ eye<br>protection/ face protection. |
|                   |                           | <b>Respons</b><br>P301 + P<br>P308 + P<br>P337 + P | <ul> <li>312 + P330 IF SWALLOWED: Call a POISON<br/>CENTER/ doctor if you feel unwell. Rinse mouth.</li> <li>313 IF exposed or concerned: Get medical advice/<br/>attention.</li> </ul>         |

Hazardous components which must be listed on the label: Moxifloxacin HCL

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

| Chemical name                                | CAS-No.<br>EC-No.<br>Index-No.<br>Registration number | Classification   | Concentration<br>(% w/w) |
|--|---|--|--------------------------|
| Moxifloxacin HCL                             | 186826-86-8   | Acute Tox. 4; H302<br>Eye Irrit. 2; H319<br>Repr. 2; H361d<br>STOT RE 2; H373<br>(Liver) | >= 40 - <= 70            |
| Substances with a workplace exposure limit : |   |  |                          |
| Cellulose                                    | 9004-34-6   |  | >= 10 - <= 30            |



### Moxifloxacin Solid Formulation

| Version<br>3.5 | Revision Date: 28.09.2024 | SDS Number:<br>9839712-00009 | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021 | - |
|----------------|---------------------------|------------------------------|---|---|
|                |                           | 232-674-9                    |   |   |
| Eor e          | valenation of abbrevia    | 232-674-9                    |   |   |

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures General advice In the case of accident or if you feel unwell, seek medical ad-: vice immediately. When symptoms persist or in all cases of doubt seek medical advice. Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). If inhaled : If inhaled, remove to fresh air. Get medical attention. In case of skin contact In case of contact, immediately flush skin with soap and plenty : of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. In case of contact, immediately flush eyes with plenty of water In case of eye contact : for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention. If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. 4.2 Most important symptoms and effects, both acute and delayed : Harmful if swallowed. Risks Causes serious eye irritation. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. 4.3 Indication of any immediate medical attention and special treatment needed Treatment : Treat symptomatically and supportively.



### **Moxifloxacin Solid Formulation**

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.5     | 28.09.2024     | 9839712-00009 | Date of first issue: 13.10.2021 |

### **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

| Suitable extinguishing media     | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO2)<br>Dry chemical |
|----------------------------------|---|---|
| Unsuitable extinguishing media   | : | None known.   |
| 5.2 Special hazards arising from |   | e substance or mixture  |

| Specific hazards during fire-<br>fighting        | : | Exposure to combustion products may be a hazard to health.  |
|--|---|---|
| Hazardous combustion prod-<br>ucts               | : | Carbon oxides   |
| 5.3 Advice for firefighters                      |   |   |
| Special protective equipment<br>for firefighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |
| Specific extinguishing meth-<br>ods              | : | Use extinguishing measures that are appropriate to local cir-<br>cumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do<br>so. |

Evacuate area.

### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

| on resonar pressations, protect |   | e equipment and emergency procedures  |
|---------------------------------|---|---|
| Personal precautions            | : | Use personal protective equipment.<br>Follow safe handling advice (see section 7) and personal pro-<br>tective equipment recommendations (see section 8).   |
| 6.2 Environmental precautions   |   |   |
| Environmental precautions       | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.<br>Retain and dispose of contaminated wash water.<br>If spillage enters rivers or watercourses, inform the Environ-<br>ment Agency (emergency telephone number 0800 807060). |

### 6.3 Methods and material for containment and cleaning up

| Methods for cleaning up | : | Sweep up or vacuum up spillage and collect in suitable con-<br>tainer for disposal.  |
|-------------------------|---|--|
|                         |   | Local or national regulations may apply to releases and dis-<br>posal of this material, as well as those materials and items |



### **Moxifloxacin Solid Formulation**

| Version<br>3.5 | Revision Date: 28.09.2024 | SDS Number:<br>9839712-00009   | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021  |
|----------------|---------------------------|--------------------------------|--|
|                |                           | mine which re<br>Sections 13 a | he cleanup of releases. You will need to deter-<br>gulations are applicable.<br>nd 15 of this SDS provide information regarding<br>or national requirements. |
| 6.4 Refer      | ence to other sections    |                                |  |
| See section    | ons: 7, 8, 11, 12 and 13. |                                |  |
| SECTIO         | N 7: Handling and st      | orage                          |  |
|                | 5                         | 0                              |  |
| 7.1 Preca      | utions for safe handlir   | ng                             |  |
| Tech           | nical measures            |                                | ing measures under EXPOSURE  |
| Loca           | I/Total ventilation       |                                | PERSONAL PROTECTION section.<br>adequate ventilation.  |
|                | ce on safe handling       | : Do not breath                | e dust, fume, gas, mist, vapours or spray.   |
|                |                           | Do not swallo                  |  |
|                |                           | Do not get in<br>Avoid prolong | eyes.<br>ed or repeated contact with skin.   |
|                |                           |                                | proughly after handling.   |
|                |                           |                                | ordance with good industrial hygiene and safety<br>ed on the results of the workplace exposure as-   |
|                |                           | sessment                       | a on the results of the workplace exposure as  |
|                |                           | -                              | ink or smoke when using this product.  |
|                |                           | Take care to<br>environment.   | prevent spills, waste and minimize release to the  |
| Hygie          | ene measures              | : If exposure to               | chemical is likely during typical use, provide eye   |
|                |                           |                                | ms and safety showers close to the working   |
|                |                           |                                | using do not eat, drink or smoke. Wash contami-<br>before re-use.  |
|                |                           |                                | operation of a facility should include review of   |
|                |                           |                                |  |

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations. |
|---|---|--|
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents  |
| 7.3 Specific end use(s)                       |   |  |

| Specific use(s) | : No data available |
|-----------------|---------------------|
|-----------------|---------------------|

### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

### **Occupational Exposure Limits**

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



### **Moxifloxacin Solid Formulation**

| Vers<br>3.5 | sion Revision E<br>28.09.202 |                 |                               |                    |          |
|-------------|------------------------------|-----------------|-------------------------------|--------------------|----------|
|             | Components                   | CAS-No.         | Value type (Form of exposure) | Control parameters | Basis    |
|             | Moxifloxacin HCL             | 186826-86-<br>8 | TWA                           | 1000 µg/m3 (OEB 1) | Internal |
|             | Cellulose                    | 9004-34-6       | TWA (inhalable dust)          | 10 mg/m3           | GB EH40  |
|             |                              |                 | TWA (Respirable dust)         | 4 mg/m3            | GB EH40  |
|             |                              |                 | STEL (inhalable dust)         | 20 mg/m3           | GB EH40  |

#### 8.2 Exposure controls

### Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

| Eye/face protection                                | : | Wear safety glasses with side shields or goggles.<br>If the work environment or activity involves dusty conditions,<br>mists or aerosols, wear the appropriate goggles.<br>Wear a faceshield or other full face protection if there is a<br>potential for direct contact to the face with dusts, mists, or<br>aerosols. |
|--|---|---|
| Hand protection<br>Material                        | : | Chemical-resistant gloves   |
| Skin and body protection<br>Respiratory protection | : | Work uniform or laboratory coat.<br>If adequate local exhaust ventilation is not available or expo-<br>sure assessment demonstrates exposures outside the rec-<br>ommended guidelines, use respiratory protection.<br>Equipment should conform to BS EN 143   |
| Filter type  | : | Particulates type (P)   |

### **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

| Appearance<br>Colour<br>Odour<br>Odour Threshold | : | solid<br>pink<br>odourless<br>No data available |
|--|---|---|
| рН   | : | No data available                               |
| Melting point/freezing point                     | : | No data available                               |
| Initial boiling point and boiling                | : | No data available                               |
| range<br>Flash point                             | : | Not applicable                                  |
| Evaporation rate                                 | : | No data available                               |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



### **Moxifloxacin Solid Formulation**

| Ver<br>3.5 | sion            | Revision Date:<br>28.09.2024             | - | S Number:<br>39712-00009               | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021 |
|------------|-----------------|--|---|--|---|
|            | Flamm           | ability (solid, gas)                     |   | Not classified as                      | a flammability hazard   |
|            | Fidititi        | ability (solid, gas)                     | • | Not classified as                      |   |
|            |                 | explosion limit / Upper<br>ability limit | : | No data available                      | 9   |
|            |                 | explosion limit / Lower<br>ability limit | : | No data available                      | 9   |
|            | Vapou           | rpressure                                | : | No data available                      | 9   |
|            | Relativ         | e vapour density                         | : | No data available                      | 9   |
|            | Relativ         | e density                                | : | No data available                      | 9   |
|            | Density         | /  | : | No data available                      | 9   |
|            |                 | ter solubility<br>n coefficient: n-      | : | No data available<br>No data available |   |
|            | Auto-ig         | nition temperature                       | : | No data available                      | 9   |
|            | Decom           | position temperature                     | : | No data available                      | 9   |
|            | Viscosi<br>Visc | ity<br>cosity, kinematic                 | : | No data available                      | 9   |
|            | Explos          | ive properties                           | : | Not explosive                          |   |
|            | Oxidizi         | ng properties                            | : | The substance o                        | r mixture is not classified as oxidizing.                         |
| 9.2        | Other ir        | nformation                               |   |  |   |
|            | Flamm           | ability (liquids)                        | : | No data available                      | e   |
|            | Molecu          | ılar weight                              | : | Not applicable                         |   |
|            | Particle        | e size                                   | : | No data available                      | 9   |
|            |                 |  |   |  |   |

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Moxifloxacin Solid Formulation**

| Versi<br>3.5 | on                        | Revision Date:<br>28.09.2024                    |       | S Number:<br>39712-00009                                    | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021 |
|--------------|---------------------------|---|-------|---|---|
| 10.4         | Conditi                   | ions to avoid                                   |       |   |   |
| (            | Conditio                  | ons to avoid                                    | :     | None known.   |   |
| 10.5         | Incomp                    | patible materials                               |       |   |   |
|              | -                         | ls to avoid                                     | :     | Oxidizing agents  |   |
| 10.6         | Hazard                    | ous decomposition p                             | orod  | ucts  |   |
|              |                           | ardous decomposition                            |       |   |   |
| SEC          | TION 1                    | 11: Toxicological in                            | forr  | mation  |   |
| 11.1         | Informa                   | ation on toxicological                          | l eff | ects  |   |
| I            | Informa                   | tion on likely routes of                        |       | Skin contact  |   |
| (            | exposu                    | re  |       | Ingestion<br>Eye contact                                    |   |
|              | <b>Acute t</b><br>Harmful | <b>oxicity</b><br>I if swallowed.               |       |   |   |
| -            | Produc                    |   |       |   |   |
| /            | Acute o                   | ral toxicity                                    | :     | Acute toxicity estin<br>Method: Calculation                 |   |
| <u>(</u>     | Compo                     | nents:  |       |   |   |
| I            | Moxiflo                   | oxacin HCL:                                     |       |   |   |
| 1            | Acute o                   | ral toxicity                                    | :     | LD50 (Rat): 1,320   | mg/kg   |
|              |                           |   |       | LD50 (Mouse): > 4   | 435 mg/kg   |
|              |                           |   |       | LD50 (Monkey): 1  | ,500 mg/kg  |
| (            | Cellulo                   | se:   |       |   |   |
| /            | Acute o                   | ral toxicity                                    | :     | LD50 (Rat): > 5,00  | 00 mg/kg  |
| ,            | Acute ir                  | nhalation toxicity                              | :     | LC50 (Rat): > 5.8<br>Exposure time: 4 I<br>Test atmosphere: | า   |
| /            | Acute d                   | ermal toxicity                                  | :     | LD50 (Rabbit): > 2  | 2,000 mg/kg   |
|              |                           | orrosion/irritation<br>ssified based on availal | ble i | nformation.   |   |
| <u>(</u>     | Compo                     | nents:  |       |   |   |
| I            | Moxiflo                   | oxacin HCL:                                     |       |   |   |
|              | Species<br>Result         | 3   | :     | Rabbit<br>No skin irritation                                |   |
|              |                           |   |       |   |   |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



### **Moxifloxacin Solid Formulation**

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.5     | 28.09.2024     | 9839712-00009 | Date of first issue: 13.10.2021 |

### Serious eye damage/eye irritation

Causes serious eye irritation.

#### Components:

#### Moxifloxacin HCL:

| Species | : | Rabbit                  |
|---------|---|-------------------------|
| Result  | : | Moderate eye irritation |

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

# Germ cell mutagenicity

Not classified based on available information.

#### Components:

### **Moxifloxacin HCL:**

| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES)<br>Result: positive  |
|-----------------------|---|---|
|                       |   | Test Type: Chromosome aberration test in vitro Result: negative   |
|                       |   | Test Type: In vitro mammalian cell gene mutation test<br>Result: negative   |
|                       |   | Test Type: in vitro micronucleus test<br>Result: negative   |
| Genotoxicity in vivo  | : | Test Type: Mammalian erythrocyte micronucleus test (in vivo<br>cytogenetic assay)<br>Application Route: Oral<br>Result: negative    |
| Cellulose:            |   |   |
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES)<br>Result: negative  |
|                       |   | Test Type: In vitro mammalian cell gene mutation test Result: negative  |
| Genotoxicity in vivo  | : | Test Type: Mammalian erythrocyte micronucleus test (in vivo<br>cytogenetic assay)<br>Species: Mouse<br>Application Route: Ingestion |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Moxifloxacin Solid Formulation**

| Versior<br>3.5 |  | Revision Date:<br>28.09.2024                              |       | S Number:<br>39712-00009  | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021  |
|----------------|--|---|-------|---|--|
|                |  |   |       | Result: negative  |  |
| No             |  | <b>genicity</b><br>iified based on availa<br><b>ents:</b> | ble   | information.  |  |
| Sp<br>Ap<br>E> | ellulos<br>pecies<br>pplicatio<br>xposure<br>esult | on Route  | : : : | Rat<br>Ingestion<br>72 weeks<br>negative                                      |  |
|                | -  | i <b>ctive toxicity</b><br>ed of damaging the ui          | nboi  | n child.  |  |
| <u>Co</u>      | ompor  | ents:   |       |   |  |
| M              | oxiflox  | acin HCL:   |       |   |  |
| Ef             | ffects o   | n fertility   | :     | Species: Rat<br>Application Route   | 500 mg/kg body weight  |
|                | ffects o<br>ent                                    | n foetal develop-   | :     | Species: Monkey<br>Application Route  | o-foetal development<br>: Oral<br>oxicity: NOAEL: 10 mg/kg body weight                                       |
|                |  |   |       | Species: Rabbit<br>Application Route  | o-foetal development<br>: Intravenous injection<br>oxicity: LOAEL: 20 mg/kg body weight<br>tal malformations |
|                | eprodu<br>essmen                                   | ctive toxicity - As-<br>t                                 | :     | Some evidence of animal experimen   | f adverse effects on development, based on ts.   |
| Ce             | ellulos  | e:  |       |   |  |
|                |  | n fertility   | :     | Test Type: One-g<br>Species: Rat<br>Application Route<br>Result: negative     | eneration reproduction toxicity study<br>: Ingestion   |
|                | ffects o<br>ient                                   | n foetal develop-   | :     | Test Type: Fertility<br>Species: Rat<br>Application Route<br>Result: negative | y/early embryonic development<br>: Ingestion   |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



### **Moxifloxacin Solid Formulation**

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.5     | 28.09.2024     | 9839712-00009 | Date of first issue: 13.10.2021 |

#### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

#### Moxifloxacin HCL:

| : | Liver<br>May cause damage to organs through prolonged or repeated<br>exposure. |
|---|--|
|   | exposure.  |
|   | :  |

### **Repeated dose toxicity**

### **Components:**

| Moxifloxacin HCL:<br>Species<br>LOAEL<br>Application Route<br>Exposure time         | :                | Rat<br>100 mg/kg<br>Oral<br>4 Weeks  |
|---|------------------|--|
| Species<br>NOAEL<br>Application Route<br>Exposure time<br>Target Organs<br>Symptoms | ·<br>·<br>·      | Rat<br>100 mg/kg<br>Oral<br>13 Weeks<br>Liver<br>Liver disorders             |
| Species<br>NOAEL<br>Application Route<br>Exposure time<br>Target Organs<br>Symptoms | ·<br>·<br>·<br>· | Rat<br>20 mg/kg<br>Oral<br>6 Months<br>Liver<br>Liver disorders              |
| Species<br>NOAEL<br>Application Route<br>Exposure time<br>Symptoms                  | :                | Monkey<br>50 mg/kg<br>Oral<br>4 Weeks<br>No adverse effects                  |
| Species<br>NOAEL<br>Application Route<br>Exposure time<br>Target Organs<br>Symptoms | ·<br>·<br>·      | Monkey<br>15 mg/kg<br>Oral<br>13 Weeks<br>Gastrointestinal tract<br>Vomiting |
| Species<br>Application Route<br>Exposure time                                       | :                | Monkey<br>Oral<br>26 Weeks   |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



# **Moxifloxacin Solid Formulation**

| Version<br>3.5                                   | Revision Date:<br>28.09.2024   |  | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021  |
|--|--|--|--|
| Targe<br>Symp                                    | et Organs<br>otoms   | : Liver<br>: Liver disorders                 |  |
| <b>Cellu</b><br>Speci<br>NOAE                    | es   | : Rat<br>: >= 9,000 mg/kg                    |  |
|  | cation Route<br>sure time  | : Ingestion<br>: 90 Days                     |  |
| -  | ration toxicity<br>lassified based on ava                              | able information.                            |  |
| Expe   | rience with human ex   | posure                                       |  |
| <u>Com</u>                                       | oonents:   |  |  |
| Moxi   | floxacin HCL:  |  |  |
| Inges  | tion   |  | a, Abdominal pain, Headache, Dizziness,<br>stem effects, joint pain  |
| SECTION  | 12: Ecological inf   | rmation                                      |  |
| 2.1 Toxic  | city   |  |  |
| Com  | ponents:   |  |  |
| Cellu  | lose:  |  |  |
| Toxic  | ity to fish  | Exposure time: 48                            | bes (Japanese medaka)): > 100 mg/l<br>h<br>n data from similar materials   |
| 12.2 Persi                                       | stence and degradal  | lity   |  |
| Com  | oonents:   |  |  |
| <b>Cellu</b><br>Biode                            | <b>lose:</b><br>gradability  | : Result: Readily bio                        | degradable.  |
| 12.3 Bioa  | ccumulative potentia   |  |  |
| No da  | ata available  |  |  |
| 12.4 Mobi  | •  |  |  |
| 1 <b>2.4 Mobi</b><br>No da                       | ata available<br>lity in soil  | ssessment                                    |  |
| 1 <b>2.4 Mobi</b><br>No da                       | ata available<br>lity in soil<br>ata available<br>ilts of PBT and vPvB | ssessment                                    |  |
| 12.4 Mobi<br>No da<br>12.5 Resu<br><u>Prod</u> e | ata available<br>lity in soil<br>ata available<br>ilts of PBT and vPvB | : This substance/mix<br>to be either persist | ture contains no components considered<br>ent, bioaccumulative and toxic (PBT), or<br>I very bioaccumulative (vPvB) at levels of |



# **Moxifloxacin Solid Formulation**

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.5     | 28.09.2024     | 9839712-00009 | Date of first issue: 13.10.2021 |

#### 12.6 Other adverse effects

### Product:

| Endocrine disrupting poten-<br>tial | : | This substance/mixture does not contain components consid-<br>ered to have endocrine disrupting properties for environment<br>according to UK REACH Article 57(f). |
|-------------------------------------|---|--|
|-------------------------------------|---|--|

### **SECTION 13:** Disposal considerations

| 13.1 Waste treatment methods |  |
|------------------------------|--|
| Product                      | <ul> <li>Dispose of in accordance with local regulations.</li> <li>According to the European Waste Catalogue, Waste Codes<br/>are not product specific, but application specific.</li> <li>Waste codes should be assigned by the user, preferably in<br/>discussion with the waste disposal authorities.</li> <li>Do not dispose of waste into sewer.</li> </ul> |
| Contaminated packaging       | Empty containers should be taken to an approved waste han-<br>dling site for recycling or disposal.<br>If not otherwise specified: Dispose of as unused product.   |

### **SECTION 14: Transport information**

### 14.1 UN number

|      | ADN                          | : | Not regulated as a dangerous good |
|------|------------------------------|---|-----------------------------------|
|      | ADR                          | : | Not regulated as a dangerous good |
|      | RID                          | : | Not regulated as a dangerous good |
|      | IMDG                         | : | Not regulated as a dangerous good |
|      | ΙΑΤΑ                         | : | Not regulated as a dangerous good |
| 14.  | 2 UN proper shipping name    |   |                                   |
|      | ADN                          | : | Not regulated as a dangerous good |
|      | ADR                          | : | Not regulated as a dangerous good |
|      | RID                          | : | Not regulated as a dangerous good |
|      | IMDG                         | : | Not regulated as a dangerous good |
|      | ΙΑΤΑ                         | : | Not regulated as a dangerous good |
| 14.: | 3 Transport hazard class(es) |   |                                   |
|      | ADN                          | : | Not regulated as a dangerous good |
|      | ADR                          | : | Not regulated as a dangerous good |
|      | RID                          | : | Not regulated as a dangerous good |
|      | IMDG                         | : | Not regulated as a dangerous good |
|      | ΙΑΤΑ                         | : | Not regulated as a dangerous good |
|      |                              |   |                                   |

UK REACH Regulations SI 2019/758

According to REACH Regulation (EC) No 1907/2006, as amended by



### **Moxifloxacin Solid Formulation**

| Version<br>3.5  | Revision Date: 28.09.2024 | SDS Number:<br>9839712-00009 | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021 |  |  |  |
|---|---------------------------|------------------------------|---|--|--|--|
| 14.4 Pack   | 14.4 Packing group        |                              |   |  |  |  |
| ADN   |                           | : Not regulated a            | as a dangerous good   |  |  |  |
| ADR   |                           | : Not regulated a            | as a dangerous good   |  |  |  |
| RID   |                           | : Not regulated a            | as a dangerous good   |  |  |  |
| IMDG  |                           | : Not regulated a            | as a dangerous good   |  |  |  |
| ΙΑΤΑ  | (Cargo)                   | : Not regulated a            | as a dangerous good   |  |  |  |
| ΙΑΤΑ  | (Passenger)               | : Not regulated a            | as a dangerous good   |  |  |  |
| 14.5 Environmental hazards  |                           |                              |   |  |  |  |
| Not regulated as a dangerous good                                       |                           |                              |   |  |  |  |
| 14.6 Special precautions for user<br>Not applicable                     |                           |                              |   |  |  |  |
| 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code |                           |                              |   |  |  |  |

: Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

Remarks

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

| UK REACH List of restrictions (Annex 17)  | :   | Not applicable |
|---|-----|----------------|
| UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation                           | :   | Not applicable |
| The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Brit-  | :   | Not applicable |
| ain)<br>Regulation (EC) on substances that deplete the ozone  | :   | Not applicable |
| layer<br>UK REACH List of substances subject to authorisation   | :   | Not applicable |
| (Annex XIV)<br>GB Export and import of hazardous chemicals - Prior  | :   | Not applicable |
| Informed Consent (PIC) Regulation<br>Control of Major Accident Hazards Regulations 2015 (CC<br>Not applicable | DMA | <b>.</b> H)    |

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

### The components of this product are reported in the following inventories:

AICS : not determined



### Moxifloxacin Solid Formulation

| Version<br>3.5 | Revision Date:<br>28.09.2024                 | SDS Number:<br>9839712-00009 | Date of last issue: 06.04.2024<br>Date of first issue: 13.10.2021                            |
|----------------|--|------------------------------|--|
| DSL            |  | : not determined             |  |
| DSL            |  | . not determined             |  |
| IECS           | С  | : not determined             |  |
| A Chemic       | nical safety assessm<br>al Safety Assessment | has not been carried o       | ut.  |
|                |  |                              |  |
| Other          | - information                                |                              | anges have been made to the previous version<br>in the body of this document by two vertical |
| Full t         | ext of H-Statements                          |                              |  |
| H302           |  | : Harmful if swalle          | owed.  |
| H319           |  | : Causes serious             | •  |
| H361           | -  | •                            | amaging the unborn child.  |
| H373           |  | : May cause dam exposure.    | age to organs through prolonged or repeated  |
| Full t         | ext of other abbrevia                        | tions                        |  |
| Acute          | e Tox.                                       | : Acute toxicity             |  |

| Acute Tox.     | : | Acute toxicity   |
|----------------|---|--|
| Eye Irrit.     | : | Eye irritation   |
| Repr.          | : | Reproductive toxicity                                  |
| STOT RE        | : | Specific target organ toxicity - repeated exposure     |
| GB EH40        | : | UK. EH40 WEL - Workplace Exposure Limits               |
| GB EH40 / TWA  | : | Long-term exposure limit (8-hour TWA reference period) |
| GB EH40 / STEL | : | Short-term exposure limit (15-minute reference period) |

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office



### Moxifloxacin Solid Formulation

| Version | Revision Date: | SDS Number:   | Date of last issue: 06.04.2024  |
|---------|----------------|---------------|---------------------------------|
| 3.5     | 28.09.2024     | 9839712-00009 | Date of first issue: 13.10.2021 |

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### Further information

| Sources of key data used to<br>compile the Safety Data<br>Sheet | :               |     | data from raw material SDSs, OECD sults and European Chemicals Agen-<br>u/ |
|---|-----------------|-----|--|
| Classification of the mixtur                                    | e:              |     | Classification procedure:  |
| Acute Tox. 4  | H3(             | )2  | Calculation method   |
| Eye Irrit. 2  | H3 <sup>-</sup> | 19  | Calculation method   |
| Repr. 2   | H36             | 61d | Calculation method   |
| STOT RE 2   | H37             | 73  | Calculation method   |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN